摘要
克罗恩病(CD)的传统药物治疗存在很大局限性。生物制剂的应用开辟了CD治疗的新途径。英夫利昔(infliximab)是经批准正式用于CD治疗的首个生物制剂,本文着重介绍该药治疗CD疗效和安全性的有关临床研究,并提出尚有待进一步研究的问题。随着生物制剂的不断开发,CD的治疗有可能发生根本性变化。
Conventional drug therapy for Crohn＇s disease （CD） has some limitations. Development of biotherapy has opened a new therapeutic horizon for treating CD. Infliximab （Remicade） is the first approved biological agent for the treatment of CD. This article reviewed the efficacy and safety of infliximab therapy in CD, and several problems should be further studied. Continual development of more biological agents and biotherapy will possibly change the outcome of CD in the future.
出处
《胃肠病学》
2007年第11期646-649,共4页
Chinese Journal of Gastroenterology
